LEVETIRACETAM DEXCEL 500

País: Israel

Idioma: inglés

Fuente: Ministry of Health

Ingredientes activos:

LEVETIRACETAM

Disponible desde:

DEXCEL PHARMA TECHNOLOGIES LTD

Código ATC:

N03AX14

formulario farmacéutico:

TABLETS

Composición:

LEVETIRACETAM 500 MG

Vía de administración:

PER OS

tipo de receta:

Required

Fabricado por:

DEXCEL LTD, ISRAEL

Grupo terapéutico:

LEVETIRACETAM

Área terapéutica:

LEVETIRACETAM

indicaciones terapéuticas:

Levetiracetam Dexcel is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patients from 16 years of age with newly diagnosed epilepsy.Levetiracetam Dexcel is indicated as adjunctive therapy:• In the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy.• In the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.• In the treatment of primary generalised tonic-clonic seizures in adults and adolescents from 12 years of age with Idiopathic Generalised Epilepsy.

Fecha de autorización:

2018-03-31